English

IOVANCE BIOTHERAPEUTICS, INC.

EDGAR

IOVA Current report (8-K) · filed 2026-10-29

Annual consolidated revenue for 2025: about Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 263.5M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 164.1M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

99.3 million Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA

2026 Q2 · Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA

Exact inputs and evidence

Revenue: 99313000 Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA Source

Operating margin

-52.26%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -51905000 Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA Source
Revenue: 99313000 Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA Source

Cash and cash equivalents: 111 million Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA 2026-06-30 Source
Exact value

110768000 Unit_Standard_USD_sRIcmhY4F0Krj44BausTpA
Long-term debt including current maturities: Not available
Shares outstanding: 453 million Unit_Standard_shares_CmHTyMjrD0qqbGtiH015DA 2026-06-30 Source
Exact value

452971016 Unit_Standard_shares_CmHTyMjrD0qqbGtiH015DA

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+60.6%

Prior period

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 164.07 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 263.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

263502000 − 164070000 = 99432000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w

164070000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
263502000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Year-over-year change in Revenue: 99432000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 263502000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2845083 Filing: 000110465926018899 Input fundies:Revenue: 164070000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2846983 Filing: 000110465926018899
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 18.82 million

Prior period

−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 372.18 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 391 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-391000000 − -372177000 = -18823000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w

-372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Year-over-year change in Net income: -18823000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2377861 Filing: 000110465926018899 Input fundies:NetIncome: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2218934 Filing: 000110465926018899
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 50.58 million

Prior period

−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 352.98 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 302.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-302400000 − -352977000 = 50577000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w

-352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Year-over-year change in Operating cash flow: 50577000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2378199 Filing: 000110465926018899 Input fundies:OperatingCashFlow: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2280879 Filing: 000110465926018899
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+205.7%

Prior period

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 11.07 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 33.84 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

33836000 − 11069000 = 22767000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w

11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Year-over-year change in Capital expenditure: 22767000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2298022 Filing: 000110465926018899 Input fundies:CapitalExpenditure: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2299179 Filing: 000110465926018899
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 263.5 million 100% of revenue
Operating costs Derived Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 666.86 million 253% of revenue
Operating income −Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 403.36 million −153% of revenue
Tax, interest and other Derived −Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 12.36 million −4.7% of revenue
Net income −Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 391 million −148% of revenue

Cash

Operating cash flow −Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 302.4 million −115% of revenue
Capital expenditure Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 33.84 million 13% of revenue
Free cash flow Derived −Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 336.24 million −128% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 38,835% of revenue.
2024 Operating loss: operating costs were 341% of revenue.
2025 Operating loss: operating costs were 253% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	1189000	461748000 Derived	-460559000	-16522000 Derived	-444037000	-384110000 Derived	Source 2023-01-01 – 2023-12-31: 1189000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Revenue Open source 2023-01-01 – 2023-12-31: -460559000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -444037000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source 2023-01-01 – 2023-12-31: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	164070000	559348000 Derived	-395278000	-23101000 Derived	-372177000	-364046000 Derived	Source 2024-01-01 – 2024-12-31: 164070000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Revenue Open source 2024-01-01 – 2024-12-31: -395278000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source 2024-01-01 – 2024-12-31: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	263502000	666858000 Derived	-403356000	-12356000 Derived	-391000000	-336236000 Derived	Source 2025-01-01 – 2025-12-31: 263502000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Revenue Open source 2025-01-01 – 2025-12-31: -403356000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source 2025-01-01 – 2025-12-31: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 263.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w)	Source evidence
20232023-12-31	Revenue	1189000	Revenue: 1189000 Open source
20242024-12-31	Revenue	164070000	Revenue: 164070000 Open source
20252025-12-31	Revenue	263502000	Revenue: 263502000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

60.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 1189000 Open source
20242024-12-31	Year over year	13,699%	Revenue: 164070000 Open source Revenue: 1189000 Open source
20252025-12-31	Year over year	60.6%	Revenue: 263502000 Open source Revenue: 164070000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -153.1% 2025

Net margin -148.4% 2025

Free cash flow margin -127.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-38,735%	Operating Income: -460559000 Open source Revenue: 1189000 Open source
20242024-12-31	Operating margin	-240.9%	Operating Income: -395278000 Open source Revenue: 164070000 Open source
20252025-12-31	Operating margin	-153.1%	Operating Income: -403356000 Open source Revenue: 263502000 Open source
20232023-12-31	Net margin	-37,345.4%	Net Income: -444037000 Open source Revenue: 1189000 Open source
20242024-12-31	Net margin	-226.8%	Net Income: -372177000 Open source Revenue: 164070000 Open source
20252025-12-31	Net margin	-148.4%	Net Income: -391000000 Open source Revenue: 263502000 Open source
20232023-12-31	Free cash flow margin	-32,305.3%	Revenue: 1189000 Open source Operating Cash Flow: -361820000 Open source Capital Expenditure: 22290000 Open source
20242024-12-31	Free cash flow margin	-221.9%	Revenue: 164070000 Open source Operating Cash Flow: -352977000 Open source Capital Expenditure: 11069000 Open source
20252025-12-31	Free cash flow margin	-127.6%	Revenue: 263502000 Open source Operating Cash Flow: -302400000 Open source Capital Expenditure: 33836000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w -302.4M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w)	Source evidence
20232023-12-31	Operating cash flow	-361820000	Operating Cash Flow: -361820000 Open source
20242024-12-31	Operating cash flow	-352977000	Operating Cash Flow: -352977000 Open source
20252025-12-31	Operating cash flow	-302400000	Operating Cash Flow: -302400000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w -336.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w)	Source evidence
20232023-12-31	Free cash flow	-384110000	Operating Cash Flow: -361820000 Open source Capital Expenditure: 22290000 Open source
20242024-12-31	Free cash flow	-364046000	Operating Cash Flow: -352977000 Open source Capital Expenditure: 11069000 Open source
20252025-12-31	Free cash flow	-336236000	Operating Cash Flow: -302400000 Open source Capital Expenditure: 33836000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 444.04 million Exact value Exact value: -444037000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2023-01-01 – 2023-12-31: -444037000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source Share or cite Citation for Net Income · IOVANCE BIOTHERAPEUTICS, INC. · 2023-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Net Income: -444037000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:NetIncome: -444037000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2219889 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 361.82 million Exact value Exact value: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2023-01-01 – 2023-12-31: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IOVANCE BIOTHERAPEUTICS, INC. · 2023-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Operating Cash Flow: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:OperatingCashFlow: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2281934 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 22.29 million Exact value Exact value: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2023-01-01 – 2023-12-31: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IOVANCE BIOTHERAPEUTICS, INC. · 2023-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Capital Expenditure: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:CapitalExpenditure: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2300336 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 384.11 million Calculation and evidence -361820000 − 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Exact free cash flow: -384110000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2023-01-01 – 2023-12-31: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IOVANCE BIOTHERAPEUTICS, INC. · 2023-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Free cash flow: -384110000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -361820000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2281934 Filing: 000110465926018899 Input fundies:CapitalExpenditure: 22290000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2300336 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 372.18 million Exact value Exact value: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2024-01-01 – 2024-12-31: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source Share or cite Citation for Net Income · IOVANCE BIOTHERAPEUTICS, INC. · 2024-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Net Income: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:NetIncome: -372177000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2218934 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 352.98 million Exact value Exact value: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2024-01-01 – 2024-12-31: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IOVANCE BIOTHERAPEUTICS, INC. · 2024-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Operating Cash Flow: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:OperatingCashFlow: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2280879 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 11.07 million Exact value Exact value: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2024-01-01 – 2024-12-31: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IOVANCE BIOTHERAPEUTICS, INC. · 2024-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Capital Expenditure: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:CapitalExpenditure: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2299179 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 364.05 million Calculation and evidence -352977000 − 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Exact free cash flow: -364046000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2024-01-01 – 2024-12-31: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IOVANCE BIOTHERAPEUTICS, INC. · 2024-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Free cash flow: -364046000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -352977000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2280879 Filing: 000110465926018899 Input fundies:CapitalExpenditure: 11069000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2299179 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 391 million Exact value Exact value: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2025-01-01 – 2025-12-31: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Net Income Open source Share or cite Citation for Net Income · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Net Income: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:NetIncome: -391000000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2377861 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 302.4 million Exact value Exact value: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2025-01-01 – 2025-12-31: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Operating Cash Flow: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:OperatingCashFlow: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2378199 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 33.84 million Exact value Exact value: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2025-01-01 – 2025-12-31: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Capital Expenditure: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w&dimensions= Input fundies:CapitalExpenditure: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2298022 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 336.24 million Calculation and evidence -302400000 − 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Exact free cash flow: -336236000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w 2025-01-01 – 2025-12-31: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IOVANCE BIOTHERAPEUTICS, INC. · 2025-12-31 IOVANCE BIOTHERAPEUTICS, INC. (edgar:1425205) Free cash flow: -336236000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:42:39Z Snapshot: dafe680f99bc9b1d0a63374454bb1ca8b74cfb7f63889f4b76580e0c5be4ac12 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1425205?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -302400000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2378199 Filing: 000110465926018899 Input fundies:CapitalExpenditure: 33836000 Unit_Standard_USD_FxppulhUBkSOuG0QOnjl1w (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm#2298022 Filing: 000110465926018899 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

133 filings · 5,760 latest values · 5,760 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001425205, 1425205, IOVA, LBIO, edgar:1425205

Also known as FREIGHT MANAGEMENT CORP, Genesis Biopharma, Inc, IOVANCE BIOTHERAPEUTICS, INC., IOVANCE BIOTHERAPEUTICS, INC., Lion Biotechnologies, Inc.

IOVANCE BIOTHERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation